End of 2023 Newsletter

15 December 2023

The end of the year might be approaching, but we’re not winding down at REPROCELL. The final half of 2023 has brought new services, collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This includes our launch of GMP MSC production services (in our Clinical Stem Cell Services), Pharmacology-AI machine earning services. And in case you missed it, earlier in 2023 we also launched our Clinical Laboratory Services.

Here are some other things we have been up to:

On the REPROCELL Blog

Exploring CHIR99021: The Key to Stem Cell Research and Beyond

Data Privacy and Protection in AI for Precision Medicine

Bias in AI for precision medicine

Editing B2M and CIITA to Create Hypoimmune Cell Lines for Cell Therapy

REPROCELL Webinars

Production of Mesenchymal Stem Cells (MSCs) for Clinical and Research Projects

REPROCELL Corporate News

REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study

REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs

Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market

---

You can find out more about our end of the year shipping schedule here.

If you have any questions about our products and services, please contact us.

We hope you enjoy the festive break and start back into 2024 rested and refreshed!

---

Corporate news by tag

1. 3D Cell Culture
2. Clinical Capabilities
3. Drug Discovery
4. Genomic Services
5. GMP
6. Human Tissue Samples
7. Human Tissue Testing
8. Life Sciences
9. Master Cell Banks
10. Precision Medicine
11. Product Catalog
12. Regenerative Medicine
13. Stem Cells
14. Volunteer Registry

 Corporate news archive